CIRM Funded Clinical Trials

Autologous iPSC-derived Retinal Pigment Epithelium Cell Therapy to Restore Vision in Blinding Eye Disease

Disease Area:

Age-related macular degeneration

Investigator:

Steven Schwartz

Institution:

Cellio Therapeutics

CIRM Grant:

CLIN2-19416 (Pre-Active)

Award Value:

$7,886,551.00

Trial Sponsor:

Cellio Therapeutics

Trial Stage:

Phase 1

Trial Status:

Launching

Targeted Enrollment:

N/A